INVERNESS MEDICAL INNOVATIONS INC Form 425 June 07, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2010 INVERNESS MEDICAL INNOVATIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware 1-16789 04-3565120

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

51 Sawyer Road, Suite 200 Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

(781) 647-3900

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- b Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On June 7, 2010, Inverness Medical Innovations, Inc. issued a press release announcing that it had further extended its offer to exchange up to \$100,000,000 in aggregate principal amount of its 7.875% Senior Notes due 2016 that have been registered under the Securities Act of 1933, as amended, for a like principal amount of its outstanding unregistered 7.875% Senior Notes due 2016, to 5:00 p.m., New York City time, on Friday, June 11, 2010, unless further extended.

A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release dated June 7, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVERNESS MEDICAL INNOVATIONS, INC.

By: /s/ Jay McNamara
Jay McNamara
Senior Counsel Corporate & Finance

Date: June 7, 2010

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release dated June 7, 2010